Glucocorticoid-induced osteoporosis

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Current Rheumatology Reports

• Publication date

  2000-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11926-996-0069-4PMID 11123040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis

  2007cited by this paper
• Testosterone therapy in glucocorticoid-treated men

  2006cited by this paper
• Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

  2001cited by this paper
• Glucocorticoid-induced osteoporosis.

  2001cited by this paper
• Osteoporosis prevention, diagnosis, and therapy.

  2001cited by this paper
• Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting.

  2001influential reference
• Inhaled Corticosteroids Reduce Bone Mineral Density in Early Postmenopausal but Not Premenopausal Asthmatic Women

  2001cited by this paper
• Public health impact of adverse bone effects of oral corticosteroids.

  2001cited by this paper
• Sex steroids and bone.

  2001cited by this paper
• Molecular mechanisms of glucocorticoid-induced osteoporosis.

  2001cited by this paper
• Alendronate for the prevention of bone loss in patients on inhaled steroid therapy.

  2001cited by this paper
• Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy

  2000cited by this paper
• Use of oral corticosteroids in the United Kingdom.

  2000cited by this paper
• Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis

  2000cited by this paper
• Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip.

  2000cited by this paper
• Corticosteroids Do Not Alter the Threshold for Vertebral Fracture

  2000cited by this paper
• Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.

  2000cited by this paper
• Corticosteroids and Fractures: A Close Encounter of the Third Cell Kind

  2000cited by this paper
• A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.

  2000cited by this paper
• Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid‐Induced Osteoporosis in Men and Women: A Randomized Trial

  2000cited by this paper
• Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

  2000cited by this paper
• Use of Oral Corticosteroids and Risk of Fractures

  2000cited by this paper
• Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  1999cited by this paper
• The clinical tolerability profile of alendronate.

  1999cited by this paper
• The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate.

  1999cited by this paper
• Prophylactic Use of Alfacalcidol in Corticosteroid-Induced Osteoporosis

  1999cited by this paper
• Reduction in Transforming Growth Factor β Receptor I Expression and Transcription Factor CBFa1 on Bone Cells by Glucocorticoid*

  1998cited by this paper
• Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study

  1998cited by this paper
• A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment

  1998cited by this paper
• Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

  1998cited by this paper
• Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

  1998cited by this paper
• Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

  1998cited by this paper
• Low incidence of osteoporosis in a two year follow-up of early community based patients with rheumatoid arthritis.

  1998cited by this paper
• Corticosteroid-induced bone loss in men.

  1998cited by this paper
• Calcium and vitamin D for corticosteroid-induced osteoporosis.

  1998cited by this paper
• Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

  1998cited by this paper
• Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.

  1998cited by this paper
• Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.

  1997cited by this paper
• Management of hepatic encephalopathy.

  1997cited by this paper
• Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intermittent Intravenous Pamidronate: A Randomized Trial

  1997cited by this paper
• The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid‐treated patients with giant‐cell arteritis

  1997cited by this paper
• Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

  1997cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• Intermittent etidronate and corticosteroid-induced osteoporosis.

  1997cited by this paper
• Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study.

  1997cited by this paper
• Prevention of Corticosteroid-Induced Osteoporosis with Alendronate in Sarcoid Patients

  1997cited by this paper
• Testosterone therapy in glucocorticoid-treated men.

  1996cited by this paper
• Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup.

  1996cited by this paper
• Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

  1996cited by this paper
• Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

  1996cited by this paper
• Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis

  1996cited by this paper
• Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.

  1996cited by this paper
• Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis.

  1996cited by this paper
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  1996cited by this paper
• Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis.

  1995cited by this paper
• Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

  1995cited by this paper
• Intact parathyroid hormone levels are not elevated in glucocorticoid‐treated subjects

  1995cited by this paper
• Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study.

  1994cited by this paper
• Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids.

  1994cited by this paper
• Pathogenesis of vertebral crush fractures in women.

  1994cited by this paper
• Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids.

  1994cited by this paper
• Mechanisms of rapid bone loss following cardiac transplantation

  1994cited by this paper
• Generalised bone loss in patients with early rheumatoid arthritis.

  1994cited by this paper
• Epidemiology and clinical features of osteoporosis in young individuals.

  1994cited by this paper
• Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss.

  1994cited by this paper
• The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932.

  1994cited by this paper
• Hepatic expression of hepatocyte-growth-factor-like/macrophage-stimulating protein mRNA in fulminant hepatic failure.

  1994cited by this paper
• Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

  1993cited by this paper
• Effects of corticosteroids on bone turnover.

  1993cited by this paper
• Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis

  1993cited by this paper
• Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: A biochemical and histomorphometric study

  1993cited by this paper
• Diagnosis of Osteoporosis

  1992cited by this paper
• Corticosteroid effects on proximal femur bone loss

  1990cited by this paper
• Bone loss in response to long-term glucocorticoid therapy.

  1990cited by this paper
• Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

  1990cited by this paper
• Long‐term effects of physiologic concentrations of dexamethasone on human bone‐derived cells

  1990cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management.

  1990cited by this paper
• Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

  1990cited by this paper
• Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids.

  1986cited by this paper
• Steroid-induced fractures and bone loss in patients with asthma.

  1983cited by this paper
• Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy.

  1983cited by this paper
• Glucocorticoid-induced osteoporosis.

  1983cited by this paper

• Dental implant considerations in patients with systemic diseases: An updated comprehensive review.

  2024cites this paper
• Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte.

  2018cites this paper
• Application of systems biology to dissect glucocorticoid receptor function

  2013cites this paper
• Glucocorticoids and osteocyte autophagy.

  2013cites this paper
• Fisetin prevents fluoride- and dexamethasone-induced oxidative damage in osteoblast and hippocampal cells.

  2012cites this paper
• Green tea polyphenols mitigate bone loss of female rats in a chronic inflammation-induced bone loss model.

  2010cites this paper
• Synergistic effects of green tea polyphenols and alphacalcidol on chronic inflammation-induced bone loss in female rats

  2010cites this paper
• Green tea polyphenols attenuate deterioration of bone microarchitecture in female rats with systemic chronic inflammation

  2010cites this paper
• Cost-effectiveness analyses of anti-resorptive agents for management of glucocorticoid-induced osteoporosis and fractures: Empirical estimates from the 1996--2004 MEPS data and longitudinal projection from Markov modeling

  2007cites this paper
• Compositions d'extrait de rocou, y compris les géraniols géranyl et procédés d'utilisation

  2004cites this paper
• Annattoextraktzusammensetzungen einschließlich Geranylgeraniole und Verwendungsverfahren

  2004cites this paper
• An update on glucocorticoid-induced osteoporosis.

  2001cites this paper